Qu Yuanyuan, Ye Dingwei, Dai Bo, Kong Yunyi, Chang Kun, Gu Chengyuan, Sun Zijie, Zhang Hailiang, Zhu Yao, Shi Guohai
Department of Urology, Cancer Hospital of Fudan University, Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Email:
Zhonghua Wai Ke Za Zhi. 2014 Aug;52(8):622-6.
To investigate the impact of androgen receptor splice variant 7 (AR-V7) expression on overall survival for patients with metastatic prostate cancer.
The data of 113 diagnosed metastatic prostate cancer patients from January 2002 to June 2010 were collected retrospectively, including patient's age at diagnosis, prostate-specific antigen (PSA) level at diagnosis,Gleason score, clinical stage, PSA nadir during hormonal therapy, the time to PSA nadir, vital status, survival time and cause of death. The expression of AR-V7 in prostate cancer tissue was detected by using immunohistochemical staining. The correlation of AR-V7 expression and patient clinicopathological characteristics in all patients were analysed using Student t-test or Chi-square test. Cox proportional hazards regression models were used to evaluate the predictive role of AR-V7 expression and patient characteristics for overall survival.
The median PSA nadir was 0.7 µg/L (ranged from 0.0 to 143.0 µg/L). The median time to PSA nadir was 8.1 months (ranged from 0.9 to 71.0 months). The follow-up was performed until March 12, 2014. During the follow-up period, 67 of 113 metastatic prostate cancer patients (59.3%) died and the median overall survival was 96 months (ranged from 5 to 135 months). The AR-V7 detection rate was 20.4% (23/113). The serum PSA level in patients with positively expression of AR-V7 was significantly higher than that without AR-V7 expression (t = 2.521, P = 0.013). Multivariate Cox regression analysis indicated that the expression of AR-V7 (HR = 2.421, P = 0.002) and time to PSA nadir (HR = 1.019, P = 0.022) were independent prognostic factors of overall survival for metastatic prostate cancer patients.
The expression of AR-V7 in prostate cancer tissues and time to PSA nadir during hormonal therapy are independent prognostic factors of overall survival for metastatic prostate cancer patients. Therapy targeting AR-V7 may improve prognosis of metastatic prostate cancer patients.
探讨雄激素受体剪接变异体7（AR-V7）表达对转移性前列腺癌患者总生存期的影响。
回顾性收集2002年1月至2010年6月期间113例确诊的转移性前列腺癌患者的数据，包括诊断时的年龄、诊断时的前列腺特异性抗原（PSA）水平、 Gleason评分、临床分期、激素治疗期间的PSA最低点、达到PSA最低点的时间、生命状态、生存时间和死亡原因。采用免疫组织化学染色检测前列腺癌组织中AR-V7的表达。采用Student t检验或卡方检验分析所有患者中AR-V7表达与患者临床病理特征的相关性。采用Cox比例风险回归模型评估AR-V7表达和患者特征对总生存期的预测作用。
PSA最低点中位数为0.7μg/L（范围为0.0至143.0μg/L）。达到PSA最低点的中位时间为8.1个月（范围为0.9至71.0个月）。随访至2014年3月12日。随访期间，113例转移性前列腺癌患者中有67例（59.3%）死亡，总生存期中位数为96个月（范围为5至135个月）。AR-V7检测率为20.4%（23/113）。AR-V7阳性表达患者的血清PSA水平显著高于无AR-V7表达患者（t = 2.521，P = 0.013）。多因素Cox回归分析表明，AR-V7表达（HR = 2.421，P = 0.002）和达到PSA最低点的时间（HR = 1.019，P = 0.022）是转移性前列腺癌患者总生存期的独立预后因素。
前列腺癌组织中AR-V7的表达以及激素治疗期间达到PSA最低点的时间是转移性前列腺癌患者总生存期的独立预后因素。针对AR-V7的治疗可能改善转移性前列腺癌患者的预后。
